Introduction
============

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of autoantibodies, formation of immune complexes and subsequent deposition in target tissues with resultant local inflammation and organ damage \[[@B1]\]. Nearly every organ system can be involved in lupus with the most prominent being the kidneys, joints, skin and brain \[[@B1]\]. The major determinant of morbidity and mortality is renal involvement, although infection and cardiovascular disease are leading causes of death. The American College of Rheumatology outlines the most common disease outcomes of SLE in the 1997 revised classification criteria including arthritis, serositis, nephritis, immune-mediated cytopenias, and lupus-specific autoantibody positivity. Commonly, the course of disease will include periods of remission and flares and the disease presentation is heterogeneous among patients making SLE a difficult disease to characterize, diagnose, and study. Similar to most autoimmune diseases, lupus is believed to result from an environmental event triggering disease in a genetically susceptible individual.

Increasing evidence suggests that dysregulation of the transcription factor Fli1 contributes to the pathogenesis of lupus. Fli1 is a member of the Ets family of transcription factors and is preferentially expressed in endothelial and hematopoietic cell lineages. Levels of expression are linked to the pathogenesis of lupus. During lymphoid development, Fli1 is highly expressed in immune cells including mature B cells, pre-T cells, and resting, mature T cells \[[@B2]\]. Over-expression of Fli1 in peripheral blood mononuclear cells (PBMCs) in lupus patients is correlated with disease activity \[[@B3]\]. Fli1 is over-expressed in several lupus mouse models including T cells of NZB/NZW f1 mice and spleen of MRL/lpr mice \[[@B3],[@B4]\]. Transgenic global over-expression of Fli1 in healthy, non-autoimmune prone mice results in a lupus-like phenotype with the presence of autoreactive lymphocytes, autoantibodies and the development of immune complex mediated kidney disease \[[@B5]\]. Conversely, reduction of Fli1 levels by 50% in MRL/lpr and NZM2410 lupus-prone mice improved the disease phenotypes in these models by decreasing autoantibody production and kidney disease and significantly prolonging survival \[[@B4],[@B6]\]. This evidence demonstrates that expression levels of Fli1 in lupus affect disease phenotype.

We demonstrated previously that a polymorphic microsatellite consisting of GA repeats within the proximal promoter of the mouse *Fli1*gene is shorter in the MRL/lpr and NZM2410 lupus mouse models compared to non-autoimmune prone BALB/c and C57BL/6 mice \[[@B7]\]. Promoter/reporter (P/R) assays demonstrated that *in vitro*activity of the mouse *Fli1*promoter in a T cell line was inversely correlated with microsatellite length. The murine and human *Fli1*promoters are highly homologous with 88% homology in the proximal promoter region, including the GA microsatellite \[[@B8]\]. Together, these studies suggested that a shorter microsatellite in the Fli1 promoter may contribute to over-expression of Fli1 and to the pathogenesis of lupus. Using clinical data and genomic DNA specimens from SLE patients and controls, we demonstrate that the human microsatellite shows a similar inverse correlation between length and promoter activity in a human T cell line and that a microsatellite length of GA~26~is significantly more prevalent in SLE patients without nephritis and tended to be more prevalent in SLE patients with serositis.

Materials and methods
=====================

Plasmid constructs
------------------

The promoter/reporter (P/R) constructs containing the -502 to -37 region of the human *Fli1*gene were generated from genomic DNA isolated from control subjects in the Carolina Lupus Study as described previously \[[@B8]\]. The -502/-37 P/R constructs analyzed were identical except for the difference in microsatellite lengths; 28, 24, 16 or 13 GA repeats. Two clones for each of the microsatellite lengths were generated and tested. All constructs were confirmed by direct sequencing.

Transfections
-------------

pGL3 h*Fli1*-502/-37 P/R constructs were transfected into the Jurkat human T cell line using Fugene (Pierce, Rockford, IL USA) following the manufacturer\'s directions. A Renilla luciferase construct was co-transfected to normalize for transfection efficiency. Cells were harvested 24 hours after transfection and cell lysates were analyzed for luciferase expression using the dual luciferase detection kit (Promega, Madison, WI USA) and quantified using a luminometer. Promoter activity as a measure of luciferase expression was compared to the pGL3 Basic empty vector. Transfections were performed at least three times in duplicate with two different clones and averaged.

Cells
-----

The Jurkat human T cell line was maintained in RPMI 1640 with 10% fetal bovine serum and antibiotics at 37°C and 5% humidity. Cells were passaged the day prior to transfection.

Microsatellite fragment length measurements
-------------------------------------------

The microsatellite containing region of the *Fli1*proximal promoter was amplified from genomic DNA from subjects in the Carolina Lupus study (CLU), SLE in Gullah Health study (SLEIGH) and the MUSC Lupus Clinic study (Clinic) using the following primers: upstream primer, hGA2Up, 5\'-/56-FAM/ATGTGTCTGGGCATCTC-3\', contains a FAM fluorescent tag; and downstream primer, GADn, 5\'-GCTAATTTTGGGAAGTGACT-3\'. The amplified, FAM-tagged PCR products were sent to the DNA Facility at Iowa State University (Ames, IA, USA) for high throughput genotyping analysis using the Applied Biosystems 3100 Genetic Analyzer (Carlsbad, CA, USA) and size marker. Several samples, including those that were used to generate the P/R constructs, were run across multiple plates to ensure consistent amplification and sizing across plates and over half of the samples were run twice. The raw sizing data were visually analyzed for peak quality followed by analysis and binning using the GeneMapper software (Applied Biosystems, Carlsbad, CA, USA). Direct sequencing of 32 of the amplified products of various lengths demonstrated that the differences in amplified product sizes were due to the length of the microsatellite and not to other sequence changes.

Subjects
--------

This study utilized subject data from three lupus cohorts. Genomic DNA was isolated from peripheral blood samples obtained from the study cohorts taken upon receiving informed consent and in compliance with the Institutional Review Board for Human Studies. All aspects of this study were conducted according to the Helsinki Declaration. The Carolina Lupus (CLU) cohort is a case-control study investigating genetic and environmental factors predisposing individuals to SLE \[[@B9]\]. Patients enrolled in the CLU study were recruited through university and community rheumatology in eastern North Carolina and South Carolina. Patients met at least 4 of the 11 revised American College of Rheumatology classification criteria for SLE \[[@B10],[@B11]\]. All patients were diagnosed with SLE between 1 January 1995 and 1 July 1999 and were enrolled in the CLU study within one year of diagnosis. Matched control subjects were recruited from state driver\'s license registries. At the time of enrollment, blood samples were taken from the study subjects for the extraction of genomic DNA.

The Systemic Lupus Erythematosus in Gullah Health (SLEIGH) study includes African American lupus patients and controls living on the Sea Islands of the South Carolina and Georgia coasts \[[@B12]\]. SLEIGH subjects represent a unique genetic group with a low percent admixture of non-African genes. Subjects enrolled in the SLEIGH study were self-identified as a member of the African American Gullah community with no known ancestors that were not of Gullah lineage. Patients in SLEIGH met at least 4 of the 11 American College of Rheumatology classification criteria for SLE \[[@B10],[@B11]\]. Patients were identified as multiplex if the diagnosis of SLE could be documented in one or more family members. Population controls in SLEIGH used for our analyses had no known family history of SLE or other autoimmune disease and were matched on age and gender to patient cases. Blood samples were taken from the study subjects at the time of enrollment for extraction of genomic DNA.

Caucasian and African American lupus patients from the MUSC clinic that met 4 of the 11 American College of Rheumatology classification criteria for SLE were included for data collection. Blood samples were taken for extraction of genomic DNA.

The clinic patients were included with the CLU study for analyses. Separate analyses were performed on the Caucasian and African American populations in order to avoid possible confounders due to population stratification. Initial analyses for the SLEIGH study data considered only patients not from multiplex families. Additional analyses were performed on the SLEIGH study data to include one multiplex patient chosen at random from each multiplex family. Within each cohort, three statistical testing approaches were considered.

Statistics
----------

P/R assay data were analyzed by the Student\'s *t*-test to identify statistically significant differences. To begin analyses of the patient cohort data, hypothesis-generating genotype tests were considered by dichotomizing into short/long alleles and using 2-df Fisher\'s exact tests (or chi-squared tests where the counts of genotypes were above five for each possible genotype) to test for association with disease between cases and controls or individual disease characteristics within cases. Next, average allele length was compared between cases and controls using a two-sample *t*-test. Lastly, due to the large number of alleles observed, the CLUMP program was used to compare each allele to all the other possible alleles. The CLUMP program, described by Sham and Curtis \[[@B13]\], allows testing each allele frequency against all other allele frequencies, using a chi-squared test statistic. Statistical analyses were performed separately on patients from the SLEIGH study while patients in the CLU and MUSC clinic cohorts were analyzed together.

Results
=======

A GA~n~dinucleotide repeat in the proximal promoter of the human Fli1 gene modulates *in vitro* promoter activity in T cells
----------------------------------------------------------------------------------------------------------------------------

A polymorphic GA~n~dinucleotide microsatellite is present in the proximal region of the human *Fli1*promoter 271 base pairs upstream (-271) from the start site of translation (Figure [1A, B](#F1){ref-type="fig"}). The location of this GA~n~repeat is homologous to the polymorphic microsatellite we recently analyzed in the mouse *Fli1*promoter \[[@B7]\]. In our previous study, deletion analyses of the human *Fli1*promoter demonstrated that the microsatellite is not required for full promoter activity in a T cell line \[[@B8]\]. However, the microsatellite was demonstrated to modulate the activity of the mouse promoter in T cells such that the shorter the microsatellite the greater the promoter activity \[[@B7]\].

![**A GA~n~microsatellite in the hFli1 promoter modulates activity in a human T cell line**. **A**. Construct showing the location of distal and proximal promoters, transcription start sites (arrows) and GA microsatellite (white box) in the Fli1 promoter. Numbering is relative to the +1 translation start site. **B**. Sequence of the human -502/-37 region is aligned with the equivalent -505/-37 region from mouse. The GA microsatellite is in bold and primer sites used to amplify the microsatellite-containing region in human genomic DNA samples are underlined. **C**. The -502 to -37 region of the human Fli1 promoter shown in B with different lengths of the GA~n~microsatellite was cloned from genomic DNA samples of unaffected controls in the CLU study into the pGL3 Basic reporter vector. Constructs were transfected into Jurkat T cells and assayed for promoter activity. Expression is presented relative to the pGL3 Basic empty vector, which was set to 1. Results are an average of three independent transfections performed with two independently derived clones. \**P*\< 0.005.](ar3189-1){#F1}

To determine if there is a similar inverse correlation between microsatellite length and promoter activity with the human *Fli1*promoter, P/R constructs containing microsatellites of 28, 24, 16, and 13 GA repeats were transfected into the Jurkat human T cell line. The pGL3 construct containing 13 GA (GA~13~) repeats resulted in the highest level of *Fli1*promoter activity (Figure [1C](#F1){ref-type="fig"}). Promoter activity decreased as microsatellite length increased with a statistically significant difference between the longest (GA~28~) and the shortest (GA~13~) alleles (*P*\< 0.001). This demonstrates that relative *Fli1*promoter activity is inversely correlated with the number of GA repeats in this human T cell line similar to our previous study of the mouse *Fli1*promoter \[[@B7]\].

Distribution of microsatellite length in patients and control subjects
----------------------------------------------------------------------

In a previous study, expression of the Fli1 gene was shown to be elevated in T cells from SLE patients compared to unaffected control subjects \[[@B3]\]. Based on our results demonstrating that the length of the microsatellite is inversely correlated to Fli1 promoter activity and that a shorter microsatellite is present in lupus-prone mouse strains \[[@B7]\], we sought to determine whether the length of the microsatellite is associated with SLE. The microsatellite-containing region of the *Fli1*promoter was amplified and length measured in the Carolina Lupus (CLU) study cohort, MUSC Lupus Clinic (Clinic) study cohort and the SLEIGH study cohort. Demographics are presented in Table [1](#T1){ref-type="table"}. The CLU and Clinic cohorts were analyzed together and include 197 SLE patients and 162 unaffected controls. The SLEIGH cohort includes 154 patients and 97 unaffected controls and for statistical analyses, the cohort data was divided into two groups that either excluded multiplex families or included one randomly selected patient from each multiplex family.

###### 

Demographics of the study cohorts

                                      Controls   Patients           
  ----------------------------------- ---------- ------------ ----- ------------
  CLU/MUSC Clinic Caucasians          110        18-75 (39)   62    18-51 (36)
  CLU/MUSC Clinic African Americans   52         16-61 (33)   135   15-54 (37)
  SLEIGH Without multiplex patients   97         11-74 (42)   123   10-69 (37)
  SLEIGH With multiplex patients      97         11-74 (42)   154   10-70 (39)

The number of patients and controls and the median age ranges for the Carolina Lupus (CLU) study, Medical University of South Carolina (MUSC) clinic, and System Lupus Erythematosus in Gullah Health (SLEIGH) study participants.

Interestingly, following genotyping of these cohorts we observed over 20 different alleles with a range of GA repeats from 13 to 39 within these populations, indicating that this microsatellite is highly polymorphic in humans. Allele distributions for each cohort are presented in Figure [2](#F2){ref-type="fig"}. Due to the large number of alleles, the subjects were grouped into short and long alleles for statistical analyses to determine if a shorter GA microsatellite is associated with disease. Next, we compared average microsatellite length between cases and controls. No association was observed with either of these analyses (data not shown).

![**Distribution of the GA~n~microsatellite allele in patient and control subjects of the CLU and SLEIGH cohorts**. **A**. CLU Caucasian subjects. **B**. CLU African American subjects. **C**. African American patient population of the CLU cohort divided with respect to serositis occurrence. **D**. SLEIGH subjects excluding multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). **E**. SLEIGH subjects including multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). **F**. SLEIGH patient population divided with respect to nephritis occurrence. \**P*\< 0.05. All n values are representative of the number of patients, each patient having two alleles.](ar3189-2){#F2}

We performed additional analyses to explore other phenotype-genotype associations that were not initially hypothesized, specifically the possibility that a particular length may be associated with disease or a disease phenotype. Analyses of length in cases and controls in the CLU cohort were separated into Caucasians (Figure [2A](#F2){ref-type="fig"}) and African Americans due to concerns of population stratification (Figure [2B](#F2){ref-type="fig"}). In general, the distribution of alleles was similar in cases and controls. These results indicate no significant differences in the overall distribution of microsatellite length between SLE patients and unaffected controls in the CLU cohort regardless of ethnicity. The same analyses were performed with the SLEIGH cohort data. As in the CLU cohort, the overall distribution was similar between cases and controls whether the multiplex patients were excluded (Figure [2D](#F2){ref-type="fig"}) or included (Figure [2E](#F2){ref-type="fig"}). These results demonstrate no significant differences in the overall distribution of microsatellite length between SLE patients and unaffected controls in the SLEIGH cohort regardless of inclusion of multiplex patients.

Assessment of microsatellite length and lupus disease characteristics
---------------------------------------------------------------------

To determine whether microsatellite length is associated with specific disease characteristics, microsatellite length was analyzed within the patient population of the CLU and SLEIGH cohorts. Analyses conducted include microsatellite length and occurrence of arthritis, serositis, nephritis, immune-mediated cytopenias, and lupus-specific autoantibody positivity. These disease characteristics were defined using the 1997 revised American College of Rheumatology SLE classification criteria \[[@B11]\]. The disease characteristic could have occurred at any point in the patient\'s history, however, must be attributable to lupus. As with allele distribution analysis, no significant associations were observed in analyses of short and long alleles or average allele length with disease phenotypes (data not shown).

We then analyzed the occurrence of specific allele lengths with disease phenotypes. No significant associations were observed between microsatellite length and arthritis, cytopenias, or lupus-specific autoantibody positivity in the CLU Caucasian, CLU African American or SLEIGH populations (data not shown). Analyses of allele length with nephritis in the SLEIGH cohort, excluding multiplex patients, identified the 241 bp allele (GA~26~) as being more prevalent in patients that did not develop nephritis (Figure [2F](#F2){ref-type="fig"}). This difference was statistically significant after adjusting for multiple comparisons (*P*\< 0.05) (Table [2](#T2){ref-type="table"}). These results suggest that the 241 base pair allele may be protective against the development of nephritis in SLE patients in the SLEIGH population.

###### 

Summary of results

  Alleles associated with patients   CLU    SLEIGH                      
  ---------------------------------- ------ --------- ----------------- -----
  With Serositis                     none   239/241   239               239
  Without Nephritis                  none   none      241 (p \< 0.05)   241

Summary of results for the Carolina Lupus (CLU) study African American (AA) and Caucasian participants and for the Systemic Lupus Erythematosus in Gullah Health (SLEIGH) participants.

The 239 bp (GA~25~) and 241 bp (GA~26~) alleles were more prevalent in patients with serositis compared to patients without serositis in the African American CLU patients (Figure [2C](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Similarly, as shown in the results summary in Table [2](#T2){ref-type="table"} the 239 bp (GA~25~) allele was more prevalent in patients with serositis in the SLEIGH cohort. However, these differences did not remain statistically significant after adjusting for multiple comparisons. We then combined the SLEIGH cohort, which is entirely African American, and the CLU African American populations to determine whether increasing our sample size would result in significant differences. Although the 239 bp (GA~25~) allele length remained more prevalent when combining the two populations, statistical significance was not obtained (data not shown).

Discussion
==========

We previously demonstrated that a polymorphic GA~n~microsatellite in the mouse *Fli1*promoter modulates promoter activity in a T cell line and is evolutionarily conserved \[[@B7]\]. Although the GA~n~microsatellite in the mouse and human promoters is not required for promoter activity *in vitro*\[[@B7],[@B8]\], varying the length of the microsatellite in the mouse promoter modulated promoter activity in T cells with the length of the microsatellite being inversely proportional to promoter activity \[[@B7]\]. Here we determined that the *in vitro*activity of the human *Fli1*promoter also decreased as the number of GA repeats in the microsatellite increased (Figure [1C](#F1){ref-type="fig"}). The inverse relationship between microsatellite length and *Fli1*promoter activity observed in mouse and human suggests a possible functional role of the GA~n~microsatellite in the regulation of Fli1 expression.

Microsatellites occur at high frequency in the protein coding and non-coding regions of the human genome, which has raised many questions about their function in normal development and disease states \[[@B14]\]. Although there are many examples in the literature of the ability of microsatellites to affect expression of genes (including EGFR, estrogen receptor β, Kv1.5, nucleolin, acetyl CoA carboxylase, heme oxygenase I, matrix metalloproteinase 9, Cyr61, heat shock genes, collagen Iα2, and Pax6 \[[@B15]-[@B26]\]), the mechanisms involved are not entirely understood. Microsatellites are thought to function primarily by altering chromatin structure. Specifically, properties of GA microsatellites include the ability to adopt H-form DNA and bind GAGA factor. The H-DNA conformation includes both single- and triple-stranded regions that are DNase I-hypersensitive \[[@B27]\] and may provide an open chromatin configuration that allows binding of transcription factors to neighboring regulatory elements \[[@B28],[@B29]\]. GAGA factor is a protein identified in Drosophila and its binding to GA-rich sequences in promoters can repress or activate transcription through effects on nucleosomes \[[@B30]-[@B33]\]. Recently, the vertebrate homolog of GAGA factor, th-POK, was identified and demonstrated to bind GA-rich sequences \[[@B34]\]. Additionally, GA-rich sequences are thought to play a role as enhancer-blocking or insulator elements \[[@B35]\]. The Fli1 GA microsatellite was demonstrated previously to be sensitive to nuclease S1 digestion and shown to form H-DNA *in vitro*\[[@B36],[@B37]\]. Our *in vitro*experiments with both the mouse and human promoters support a role of the microsatellite in dampening promoter activity as length increases but not in complete repression of activity. How this microsatellite functions *in vivo*remains to be determined.

Previous results demonstrated that Fli1 expression is increased in mouse models of lupus \[[@B3],[@B4]\] and in T cells of SLE patients \[[@B3]\] compared to unaffected controls. Interestingly, globally decreasing Fli1 levels by 50% in two different lupus mouse models resulted in significantly improved disease, most notably improved nephritis, accompanied by significantly prolonged survival \[[@B4],[@B6]\]. Furthermore, it was demonstrated that reducing Fli1 levels by 50% in hematopoietic cells in a lupus mouse model also resulted in improved disease and survival \[[@B38]\]. Together these studies demonstrated that modulating Fli1 levels plays an important role in the progression of lupus. Based on these observations and our P/R results demonstrating that the length of the microsatellite modulates Fli1 expression, we hypothesized that a shorter microsatellite in the Fli1 promoter may lead to over-expression of Fli1 and thus may be associated with lupus or with specific disease phenotypes such as nephritis. The association of microsatellites with the occurrence of several diseases including SLE, rheumatoid arthritis, lung fibrosis, epithelial ovarian cancer, thyroid cancer, acute pancreatitis, breast cancer, and multiple neurological diseases has been reported \[[@B39]-[@B48]\].

We expected the microsatellite to be polymorphic in the human population; however, we were surprised to observe more than 20 different alleles spanning 13 to 39 GA repeats in the populations tested, including the highly genetically related SLEIGH population. The highly polymorphic nature of this microsatellite is interesting and prompted multiple analyses to explore all possible phenotype-genotype associations. Although the GA~n~microsatellite length had an effect on *Fli1*promoter activity *in vitro*, no association was identified between microsatellite allele length and the occurrence of SLE in the SLEIGH and CLU cohorts. The pathogenesis of SLE is complex and it is likely that the disease results from alterations in the expression of multiple target genes. Thus, Fli1 may contribute to the progression of disease but we believe it is more likely to be associated with a specific disease characteristic.

To determine if GA microsatellite length is associated with specific aspects of SLE we compared the presence of lupus-specific characteristics with microsatellite length. No association was observed between microsatellite length and arthritis, cytopenia or lupus specific autoantibodies. To our knowledge, it is unknown whether Fli1 plays a role in the development of arthritis or cytopenia in lupus, although it was demonstrated that reducing Fli1 levels in a lupus mouse model had no effect on total B cell or T cell numbers \[[@B4]\]. Therefore, it is not unexpected that no association between the Fli1 microsatellite and arthritis or cytopenia was observed. Based on results in lupus mouse models in which reducing Fli1 levels resulted in decreased autoantibody levels \[[@B4],[@B6]\], we expected to observe an association of the Fli1 microsatellite with autoantibody production. However, the effect of Fli1 on autoantibody levels appears to be secondary to effects on B cell activation \[[@B4]\], which may account for the apparent lack of association of the Fli1 microsatellite with autoantibodies in our study.

The 241 bp allele (GA~26~), was significantly associated with SLE patients that did not have nephritis in the SLEIGH cohort (Figure [2F](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Alleles of 239 and 241 bp, 25 and 26 GA repeats respectively, were more prevalent, although not significantly, in African American CLU patients with serositis (Figure [2C](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). *In vitro*constructs in this long size range (23 to 28 repeats) exhibited weaker activation of the *Fli1*promoter in P/R assays (Figure [1C](#F1){ref-type="fig"}), suggesting that lower Fli1 expression may be protective against nephritis and contribute to serositis. In lupus mouse models in which Fli1 levels were reduced globally or specifically in hematopoietic cells, nephritis was improved \[[@B4],[@B6],[@B38]\]. Conversely, expression of Fli1 in mouse endothelial cells controls vascular maturation and is required to maintain vascular integrity \[[@B49]\]. We speculate that a reduction in *Fli1*promoter activity and, hence, expression may disrupt endothelial cell function in lupus patients and contribute to exaggerated serositis.

These findings support previous hypotheses that the effects of Fli1 expression in different cell types are variable and aberrant expression of Fli1 can contribute to the development of disease. For example, in scleroderma, reduced expression of Fli1 in skin fibroblasts and endothelial cells is implicated in the fibrotic and vascular components of the phenotype \[[@B49]\], while in lupus elevated expression of Fli1 in mononuclear cells is thought to contribute to the disease phenotype \[[@B3]\]. It is conceivable that the 241 bp allele representing a microsatellite of 26 GA repeats may delineate a threshold length of the microsatellite. Individuals with a Fli1 GA~n~microsatellite at or above the threshold may have lower levels of Fli1 expression in their lymphocytes, which would be protective against developing lupus nephritis while individuals with a Fli1 GA~n~microsatellite at or above the threshold may have lower expression levels of Fli1 in their endothelial cells, which may contribute to serositis. However, we tested all dichotomies of short/long alleles and didn\'t observe significant differences, suggesting that increased and decreased expression of Fli1 may be modulated by a specific length of the GA microsatellite.

Conclusions
===========

In this work, we characterized a highly polymorphic microsatellite of GA repeats in the human *Fli1*promoter. Variable lengths of the GA~n~microsatellite modulated *Fli1*promoter activity *in vitro*in a human T cell line such that the shorter the microsatellite the greater the promoter activity. Although aberrant expression of *Fli1*in PBMCs was observed previously in SLE patients \[[@B3]\], specific association between microsatellite length and SLE was not observed in this study. However, the GA~26~microsatellite length was specifically associated with patients that did not have nephritis and tended to be more prevalent in African American patients with serositis. Due to the highly polymorphic nature of this microsatellite, a greater number of additional subjects in these cohorts would be required to increase the statistical power in order to determine significant associations for each allele and/or genotype, especially within the shortest and longest alleles, which appear to be relatively rare. The expression of Fli1 in different cell types may mediate pathological effects that contribute to the multifaceted role of Fli1 in SLE. A more precise understanding of how this microsatellite functions to modulate Fli1 expression in different cell types would be beneficial in determining whether this microsatellite may serve as therapeutic marker in lupus. Future studies are aimed at determining whether the length of the Fli1 GA~n~microsatellite correlates with Fli1 expression levels in primary human cells and how the GA microsatellite precisely functions to modulate expression.
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